Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging

Stroke

Volumn 43, Issue 12, 2012, Pages 3358-3363

  Peña Silva, Ricardo A ^a,b   Chu, Yi ^a   Miller, Jordan D ^c   Mitchell, Ian J ^a   Penninger, Josef M ^d   Faraci, Frank M ^a   Heistad, Donald D ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSIDAD DE LOS ANDES   (Colombia)

^c MAYO CLINIC   (United States)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Aging; Angiotensin converting enzyme 2; Cerebral arteries; Endothelium; Oxidative stress

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN CONVERTING ENZYME 2; CALCINEURIN; MESSENGER RNA; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TEMPOL; TUMOR NECROSIS FACTOR ALPHA;

AGING; ANGIOTENSIN CONVERTING ENZYME 2 DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; BRAIN ARTERY; BRAIN FUNCTION; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME DEFICIENCY; ENZYME SUBUNIT; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; AGING; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; MALE; MICE; MICE, KNOCKOUT; NADPH OXIDASE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; VASCULITIS; VASODILATION; VASODILATOR AGENTS;

EID: 84870908340     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.667063     Document Type: Article

References (46)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Yavuz BB, Yavuz B, Sener DD, Cankurtaran M, Halil M, Ulger Z, Nazli N, Kabakci G, Aytemir K, Tokgozoglu L, Oto A, Ariogul S. Advanced age is associated with endothelial dysfunction in healthy elderly subjects. Gerontology. 2008;54:153-156.
3. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA, Seals DR. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol (Lond). 2011;589(Pt 18):4545-4554.
4. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation. 2003;107:2805-2809.
5. Lind L, Berglund L, Larsson A, Sundström J. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation. 2011;123:1545-1551.
6. Mayhan WG, Arrick DM, Sharpe GM, Sun H. Age-related alterations in reactivity of cerebral arterioles: role of oxidative stress. Microcirculation. 2008;15:225-236.
7. Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007;27:1908-1918.
8. Modrick ML, Didion SP, Sigmund CD, Faraci FM. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol Heart Circ Physiol. 2009;296:H1914-H1919.
9. Zuliani G, Cavalieri M, Galvani M, Passaro A, Munari MR, Bosi C, Zurlo A, Fellin R. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia. J Neurol Sci. 2008;272:164-170.
10. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol. 2006; 100:328-335.
11. Benarroch EE. Neurovascular unit dysfunction: a vascular component of Alzheimer disease? Neurology. 2007;68:1730-1732.
12. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95:1019-1026.
13. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2007; 27:303-309.
14. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011;300:H1566-H1582.
15. Chrissobolis S, Faraci FM. Sex differences in protection against angio-tensin II-induced endothelial dysfunction by manganese superoxide dis-mutase in the cerebral circulation. Hypertension. 2010;55:905-910.
16. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cere-brovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol. 2011;300:H397-H407.
17. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke. 2003;34:2922-2929.
18. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843.
19. Turner AJ, Tipnis SR, Guy JL, Rice GI, Hooper NM. Aceh/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE. Biochemistry (Mosc). 2002;353:346-353
20. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263.
21. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007;50:1093-1098.
22. Feterik K, Smith L, Katusic ZS. Angiotensin-(1-7) causes endothelium-dependent relaxation in canine middle cerebral artery. Brain Res. 2000;873:75-82.
23. Liang W, Zhu Z, Guo J, Liu Z, Zhou W, Chin DP, Schuchat A; Beijing Joint SARS Expert Group. Severe acute respiratory syndrome, Beijing, 2003. Emerging Infect Dis. 2004;10:25-31.
24. Xie X, Xudong X, Chen J, Junzhu C, Wang X, Xingxiang W, Zhang F, Furong Z, Liu Y, Yanrong L. Age-and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78:2166-2171.
25. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.
26. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, Slutsky AS, Peterson MD, Backx PH, Penninger JM, Verma S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295:H1377-H1384.
27. Mo YJ, Huang WH, Chen DL, Chen FR. [Relationship of angiotensin- converting enzyme 2 gene polymorphism with the prognosis of hypertensive stroke patients]. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30:84-87.
28. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008;74:1610-1616.
29. Gurley SB, Coffman TM. Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. Exp Physiol. 2008;93:538-542.
30. Fan X, Wang Y, Sun K, Zhang W, Yang X, Wang S, Zhen Y, Wang J, Li W, Han Y, Liu T, Wang X, Chen J, Wu H, Hui R; Study Group for Pharmacogenomic Based Antihypertensive Drugs Selection, Effects and Side Effects, in Rural Area Chinese. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007;82:187-196.
31. Benjafield AV, Wang WY, Morris BJ. No association of angiotensin- converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. Am J Hypertens. 2004;17:624-628.
32. Lu N, Yang Y, Wang Y, Liu Y, Fu G, Chen D, Dai H, Fan X, Hui R, Zheng Y. ACE2 gene polymorphism and essential hypertension: an updated metaanalysis involving 11,051 subjects. Mol Biol Rep. 2012;39:6581-6589.
33. Kitayama J, Faraci FM, Lentz SR, Heistad DD. Cerebral vascular dysfunction during hypercholesterolemia. Stroke. 2007;38:2136-2141.
34. Kitayama J, Yi C, Faraci FM, Heistad DD. Modulation of dilator responses of cerebral arterioles by extracellular superoxide dismutase. Stroke. 2006;37:2802-2806.
35. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcir-culation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol. 2006;26:826-832.
36. Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI, Chappell MC. Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension. 2010;55:166-171.
37. Riper DV, Jayakumar L, Latchana N, Bhoiwala D, Mitchell AN, Valenti JW, Crawford DR. Regulation of vascular function by RCAN1 (ADAPT78). Arch Biochem Biophys. 2008;472:43-50.
38. Esteban V, Méndez-Barbero N, Jiménez-Borreguero LJ, Roqué M, Novensá L, García-Redondo AB, Salaices M, Vila L, Arbonés ML, Campanero MR, Redondo JM. Regulator of calcineurin 1 mediates pathological vascular wall remodeling. J Exp Med. 2011;208:2125-2139.
39. Demaree SR, Lawler JM, Linehan J, Delp MD. Ageing alters aortic antioxidant enzyme activities in Fischer-344 rats. Acta Physiol Scand. 1999;166:203-208.
40. Ungvari Z, Bailey-Downs L, Gautam T, Sosnowska D, Wang M, Monticone RE, Telljohann R, Pinto JT, de Cabo R, Sonntag WE, Lakatta EG, Csiszar A. Age-associated vascular oxidative stress, Nrf2 dysfunction, and NF-{kappa}B activation in the nonhuman primate Macaca mulatta. J Gerontol A Biol Sci Med Sci. 2011;66:866-875.
41. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119:524-530.
42. de Cavanagh EM, Inserra F, Ferder L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc Res. 2011;89: 31-40.
43. Bharadwaj MS, Strawn WB, Groban L, Yamaleyeva LM, Chappell MC, Horta C, Atkins K, Firmes L, Gurley SB, Brosnihan KB. Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction. Hypertension. 2011;58:852-858.
44. Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, Lo J, Grant MB, Zhong J, Kassiri Z, Oudit GY. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res. 2012;110:1322-1335.
45. Welches WR, Santos RA, Chappell MC, Brosnihan KB, Greene LJ, Ferrario CM. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertens. 1991;9:631-638.
46. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 1992;19(6 Pt 2):692-696.